1672. Eligibility and Outcomes of Conversion to Oral (PO) Therapy in Patients Hospitalized with Enterobacteriaceae (ENT) Urinary Tract Infection (UTI) in the United States (US): A Multicenter Analysis

摘要

Rising rates of fluoroquinolone resistance (FQ-R) and third-generation cephalosporin resistance/extended-spectrum beta-lactamases (ESBL+) have left patients with urinary tract infections (UTI) few oral options. Here, we evaluate the eligibility of hospitalized UTI patients to take PO medications and estimate the potential impact on hospital cost and length of stay (LOS).